Limits...
BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries.

Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, Ruijter Hd, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S - Eur. J. Epidemiol. (2014)

Bottom Line: BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries.Results from this study will contribute to improved cardiovascular risk prediction across different European populations.The present publication describes the rationale and design of the BiomarCaRE project.

View Article: PubMed Central - PubMed

Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.

ABSTRACT
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.

Show MeSH

Related in: MedlinePlus

Emerging and established biomarkers measured in phase 1 of the population-based cohorts (including a case-cohort set) and the disease cohorts within BiomarCaRE. NTproBNP, N-terminal pro B-type natriuretic peptide, MR-proANP mid-regional pro atrial natriuretic papetide; MR-proADM, mid-regional pro adrenomedullin; hsTnI, high-sensitivity assayed Troponin I; ApoA, apolipoprotein A1; ApoB100, apolipoprotein B100; Lp(a) Lipoprotein a; CRP, C-reactive protein
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4197377&req=5

Fig3: Emerging and established biomarkers measured in phase 1 of the population-based cohorts (including a case-cohort set) and the disease cohorts within BiomarCaRE. NTproBNP, N-terminal pro B-type natriuretic peptide, MR-proANP mid-regional pro atrial natriuretic papetide; MR-proADM, mid-regional pro adrenomedullin; hsTnI, high-sensitivity assayed Troponin I; ApoA, apolipoprotein A1; ApoB100, apolipoprotein B100; Lp(a) Lipoprotein a; CRP, C-reactive protein

Mentions: In Module 1 of the project (Fig. 2), established biomarkers are selected according to their association with the risk of CVD, and based on the expertise and knowledge of the BiomarCaRE consortium and the public domain. The BiomarCaRE consortium has already determined an extensive panel of biomarkers within the MORGAM Biomarker substudy [4]. Key established biomarkers to be addressed are high-sensitivity troponins (hsTn), natriuretic peptides, high-sensitivity C-reactive protein (CRP), lipids, and further markers of cardiomyocyte micronecrosis, inflammation, and renal function (Fig. 3). The concept of biomarkers reflecting different underlying pathways to disease progression combined in multiple biomarker risk scores has already been applied in several population-based studies [4, 14, 21, 25, 39] as well as in disease cohorts [26]. Several of those markers, in particular hsTn, hsCRP as well as growth differentiation factor 15 (GDF-15) have been proposed to guide therapy [1, 17, 24]. Commercially available assays are used to determine the levels of established biomarkers in the biomaterial of study participants.Fig. 3


BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries.

Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, Ruijter Hd, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S - Eur. J. Epidemiol. (2014)

Emerging and established biomarkers measured in phase 1 of the population-based cohorts (including a case-cohort set) and the disease cohorts within BiomarCaRE. NTproBNP, N-terminal pro B-type natriuretic peptide, MR-proANP mid-regional pro atrial natriuretic papetide; MR-proADM, mid-regional pro adrenomedullin; hsTnI, high-sensitivity assayed Troponin I; ApoA, apolipoprotein A1; ApoB100, apolipoprotein B100; Lp(a) Lipoprotein a; CRP, C-reactive protein
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4197377&req=5

Fig3: Emerging and established biomarkers measured in phase 1 of the population-based cohorts (including a case-cohort set) and the disease cohorts within BiomarCaRE. NTproBNP, N-terminal pro B-type natriuretic peptide, MR-proANP mid-regional pro atrial natriuretic papetide; MR-proADM, mid-regional pro adrenomedullin; hsTnI, high-sensitivity assayed Troponin I; ApoA, apolipoprotein A1; ApoB100, apolipoprotein B100; Lp(a) Lipoprotein a; CRP, C-reactive protein
Mentions: In Module 1 of the project (Fig. 2), established biomarkers are selected according to their association with the risk of CVD, and based on the expertise and knowledge of the BiomarCaRE consortium and the public domain. The BiomarCaRE consortium has already determined an extensive panel of biomarkers within the MORGAM Biomarker substudy [4]. Key established biomarkers to be addressed are high-sensitivity troponins (hsTn), natriuretic peptides, high-sensitivity C-reactive protein (CRP), lipids, and further markers of cardiomyocyte micronecrosis, inflammation, and renal function (Fig. 3). The concept of biomarkers reflecting different underlying pathways to disease progression combined in multiple biomarker risk scores has already been applied in several population-based studies [4, 14, 21, 25, 39] as well as in disease cohorts [26]. Several of those markers, in particular hsTn, hsCRP as well as growth differentiation factor 15 (GDF-15) have been proposed to guide therapy [1, 17, 24]. Commercially available assays are used to determine the levels of established biomarkers in the biomaterial of study participants.Fig. 3

Bottom Line: BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries.Results from this study will contribute to improved cardiovascular risk prediction across different European populations.The present publication describes the rationale and design of the BiomarCaRE project.

View Article: PubMed Central - PubMed

Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.

ABSTRACT
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.

Show MeSH
Related in: MedlinePlus